A new protocol for predicting novel GSK-3β ATP competitive inhibitors

Journal of Chemical Information and Modeling

Volumn 51, Issue 6, 2011, Pages 1431-1438

  Fang, Jiansong ^a   Huang, Dane ^a   Zhao, Wenxia ^a   Ge, Hu ^a   Luo, Hai Bin ^a   Xu, Jun ^a  

^a 132 East Circle at University City   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; ENZYME INHIBITION; MOLECULAR GRAPHICS; NEURODEGENERATIVE DISEASES; SCAFFOLDS; TOPOLOGY;

ALZHEIMER'S DISEASE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE-MOLECULAR-SIMILARITY-INDICES ANALYSIS; GLYCOGEN SYNTHASE KINASE; LEAD IDENTIFICATION; THERAPEUTIC TARGETS; THREE DIMENSIONAL QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP (3D QSAR); VIRTUAL SCREENING;

COMPUTATIONAL CHEMISTRY;

ADENOSINE TRIPHOSPHATE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; LIGAND; PROTEIN KINASE INHIBITOR;

ARTICLE; BINDING COMPETITION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REPRODUCIBILITY; SEQUENCE HOMOLOGY;

ADENOSINE TRIPHOSPHATE; BINDING, COMPETITIVE; GLYCOGEN SYNTHASE KINASE 3; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REPRODUCIBILITY OF RESULTS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 79959720368     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci2001154     Document Type: Article

References (43)

1. Cross, D. A.; Alessi, D. R.; Cohen, P.; Andjelkovich, M.; Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B Nature 1995, 378, 785-789 (Pubitemid 26004411)
2. Hoeflich, K. P.; Luo, J.; Rubie, E. A.; Tsao, M. S.; Jin, O.; Woodgett, J. R. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation Nature 2000, 406, 86-90 (Pubitemid 30460216)
3. Woodgett, J. R. Molecular cloning and expression of glycogen synthase kinase-3/factor A EMBO J. 1990, 9, 2431-2438
4. Ali, A.; Hoeflich, K. P.; Woodgett, J. R. Glycogen synthase kinase-3: properties, functions, and regulation Chem. Rev. 2001, 101, 2527-2540 (Pubitemid 35373033)
5. Eldar-Finkelman, H. Glycogen synthase kinase 3: an emerging therapeutic target Trends Mol. Med. 2002, 8, 126-132 (Pubitemid 34532638)
6. Doble, B. W.; Woodgett, J. R. GSK-3: tricks of the trade for a multi-tasking kinase J. Cell. Sci. 2003, 116, 1175-1186 (Pubitemid 36410657)
7. Martinez, A.; Castro, A.; Dorronsoro, I.; Alonso, M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation Med. Res. Rev. 2002, 22, 373-384 (Pubitemid 34620473)
8. Chen, R. H.; Ding, W. V.; McCormick, F. Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C J. Biol. Chem. 2000, 275, 17894-17899 (Pubitemid 30430843)
9. Nikoulina, S. E.; Ciaraldi, T. P.; Mudaliar, S.; Mohideen, P.; Carter, L.; Henry, R. R. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes Diabetes 2000, 49, 263-271 (Pubitemid 30071005)
10. Plyte, S. E.; Hughes, K.; Nikolakaki, E.; Pulverer, B. J.; Woodgett, J. R. Glycogen synthase kinase-3: functions in oncogenesis and development Biochim. Biophys. Acta 1992, 1114, 147-162 (Pubitemid 23008367)
11. Manoukian, A. S.; Woodgett, J. R. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways Adv. Cancer Res. 2002, 84, 203-229 (Pubitemid 34188198)
12. MacAulay, K.; Woodgett, J. R. Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes Expert Opin. Ther. Targets 2008, 12, 1265-1274
13. Summers, S. A.; Kao, A. W.; Kohn, A. D.; Backus, G. S.; Roth, R. A.; Pessin, J. E.; Birnbaum, M. J. The role of glycogen synthase kinase 3beta in insulin-stimulated glucose metabolism J. Biol. Chem. 1999, 274, 17934-17940
14. Baum, L.; Hansen, L.; Masliah, E.; Saitoh, T. Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation Mol. Chem. Neuropathol. 1996, 29, 253-261 (Pubitemid 27016933)
15. Bhat, R. V.; Budd Haeberlein, S. L.; Avila, J. Glycogen synthase kinase 3: a drug target for CNS therapies J. Neurochem. 2004, 89, 1313-1317 (Pubitemid 38802652)
16. Van, W. J.; Haefner, B. Glycogen synthase kinase-3 as drug target: from wallflower to center of attention Drug News Perspect. 2003, 16, 557-565 (Pubitemid 38094735)
17. Ajay, B. P.; Chitti, S.; Rajesh, B.; Vishnu, P. V.; Radha Kishen, J. V.; Khadar Vali, R. In silico Based Ligand Design and Docking Studies of GSK-3β Inhibitors Chem-Bio Inf. J. 2010, 10, 1-12
18. Dessalew, N.; Patel, D. S.; Bharatam, P. V. 3D QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors J. Mol. Graphics Model. 2007, 25, 885-895 (Pubitemid 46216123)
19. Zhang, N.; Jiang, Y.; Zou, J.; Zhang, B.; Jin, H.; Wang, Y.; Yu, Q. 3D QSAR for GSK-3beta inhibition by indirubin analogues Eur. J. Med. Chem. 2006, 41, 373-378
20. Kunick, C.; Lauenroth, K.; Wieking, K.; Xie, X.; Schultz, C.; Gussio, R.; Zaharevitz, D.; Leost, M.; Meijer, L.; Weber, A.; Jorgensen, F. S.; Lemcke, T. Evaluation and comparison of 3D QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones J. Med. Chem. 2004, 47, 22-36 (Pubitemid 38040487)
21. Martinez, A.; Alonso, M.; Castro, A.; Dorronsoro, I.; Gelpi, J. L.; Luque, F. J.; Perez, C.; Moreno, F. J. SAR and 3D QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors J. Med. Chem. 2005, 48, 7103-7112 (Pubitemid 41743624)
22. Zeng, M.; Jiang, Y.; Zhang, B.; Zheng, K.; Zhang, N.; Yu, Q. 3D QSAR studies on GSK-3 inhibition by aloisines Bioorg. Med. Chem. Lett. 2005, 15, 395-399 (Pubitemid 39647157)
23. Lescot, E.; Bureau, R.; Sopkova-de Oliveira Santos, J.; Rochais, C.; Lisowski, V.; Lancelot, J. C.; Rault, S. 3D QSAR and docking studies of selective GSK-3beta inhibitors. Comparison with a thieno[2,3-b]pyrrolizinone derivative, a new potential lead for GSK-3beta ligands J. Chem. Inf. Model. 2005, 45, 708-715 (Pubitemid 40795174)
24. Prasanna, S.; Daga, P. R.; Xie, A. H.; Doerksen, R. J. Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D QSAR and docking J. Comput. Aided Mol. Des. 2009, 23, 113-127
25. Patel, D. S.; Bharatam, P. V. Selectivity criterion for pyrazolo[3,4-b]pyrid[az]ine derivatives as GSK-3 inhibitors: CoMFA and molecular docking studies Eur. J. Med. Chem. 2008, 43, 949-957 (Pubitemid 351615231)
26. Xiao, J.; Guo, Z.; Guo, Y.; Chu, F.; Sun, P. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D QSAR analyses Protein Eng., Des. Sel. 2006, 19, 47-54 (Pubitemid 43162256)
27. Katritzky, A. R.; Pacureanu, L. M.; Dobchev, D. A.; Fara, D. C.; Duchowicz, P. R.; Karelson, M. QSAR modeling of the inhibition of glycogen synthase kinase-3 Bioorg. Med. Chem. 2006, 14, 4987-5002 (Pubitemid 43767124)
28. Lather, V.; Kristam, R.; Saini, J. S.; Kristam, R.; Karthikeyan, N. A.; Balaji, V. N. QSAR models for prediction of Glycogen Synthase kinase-3 beta inhibitory activity of indirubin derivatives QSAR Comb. Sci. 2008, 27, 718-728
29. Sivaprakasam, P.; Xie, A. H.; Doerksen, R. J. Probing the physicochemical and structural requirements for glycogen synthase kinase-3 alpha inhibition: 2D-QSAR for 3-anilino-4-phenylmaleimides Bioorg. Med. Chem. 2006, 14, 8210-8218 (Pubitemid 44667564)
30. Gaisina, I. N.; Gallier, F.; Ougolkov, A. V.; Kim, K. H.; Kurome, T.; Guo, S.; Holzle, D.; Luchini, D. N.; Blond, S. Y.; Billadeau, D. D.; Kozikowski, A. P. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells J. Med. Chem. 2009, 52, 1853-1863
31. The PubChem Project; National Center for Biotechnology Information: Bethesda, MD; http://pubchem.ncbi.nlm.nih.gov/. Accessed February 25, 2011).
32. Sybyl Molecular Modeling Software Package, v. 7.3.5, Tripos Inc.: St. Louis, MO, 2008.
33. Crame, R. D.; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins J. Am. Chem. Soc. 1988, 110, 5959-5967
34. Klebe, G. Molecular similarity indices in a comparative molecular field analysis (CoMFA) of drug molecules to correlate and predict their biological activity J. Med. Chem. 1994, 37, 4130-4146 (Pubitemid 24379702)
35. Gasteigner, J.; Marsili, M. A new model for calculating atomic charges in molecules Tetrahedron Lett. 1978, 19, 3181-3184
36. Stahle, L.; Wold, S. Multivariate data analysis and experimental design in biomedical research Prog. Med. Chem. 1988, 25, 291-338
37. Bush, B. L.; Nachbar, R. B., Jr. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA J. Comput.-Aided Mol. Des. 1993, 7, 587-619
38. 2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results J. Med. Chem. 1995, 38, 1060-1066
39. 2! J. Mol. Graphics Model. 2002, 20, 269-276 (Pubitemid 34017544)
40. Tropsha, A.; Gramatica, P.; Gombar, V. K. The importance of being earnest: Validation is the absolute essential for successful application and interpretation of QSPR models QSAR Comb. Sci. 2003, 22, 69-77 (Pubitemid 36717473)
41. FlexX in LeadIT 1.0; BioSolveIT: Sankt Augustin, Germany, 2009.
42. Kozikowski, A. P.; Gaisina, I. N.; Petukhov, P. A.; Sridhar, J.; King, L. T.; Blond, S. Y.; Duka, T.; Rusnak, M.; Sidhu, A. Highly potent and specific GSK-3 beta inhibitors that block Tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease ChemMedChem 2006, 1, 256-266 (Pubitemid 43700306)
43. Engler, T. A.; Malhotra, S.; Burkholder, T. P.; Henry, J. R.; Mendel, D.; Porter, W. J.; Furness, K.; Diefenbacher, C.; Marquart, A.; Reel, J. K.; Li, Y.; Clayton, J.; Cunningham, B.; McLean, J.; O'Toole, J, C.; Brozinick, J.; Hawkins, E.; Misener, E.; Briere, D.; Brier, R. A.; Wagner, J. R.; Campbell, R. M.; Anderson, B. D.; Vaughn, R.; Bennett, D. B.; Meier, T. I.; Cook, J. A. The development of potent and selective bisarylmaleimide GSK3 inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 899-903 (Pubitemid 40458620)